EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieÄquivalenzstudie

Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT)

Vance G Fowler iD, Anita F Das, Joy Lipka-Diamond, Jane E Ambler, Raymond Schuch, Roger Pomerantz, Cara Cassino, Luis Jáuregui-Peredo, Gregory J Moran, Mark E Rupp, Anne M Lachiewicz, Joseph L Kuti und 4 weitere

Clinical Infectious Diseases · 14.06.2024 · 78 (6) · 1473-1481

DOI: 10.1093/cid/ciae043 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Infectious Diseases, online erschienen am 31.01.2024. Verfasst von Vance G Fowler und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Staphylococcal Infections, Anti-Bacterial Agents, Bacteremia, Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: ContraFect Corporation, HHS, Administration for Strategic Preparedness and Response.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Novel treatments are needed for Staphylococcus aureus bacteremia, particularly for methicillin-resistant S. aureus (MRSA). Exebacase is a first-in-class antistaphylococcal lysin that is rapidly bactericidal and synergizes with antibiotics.

Methods

In Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase (DISRUPT), a superiority-design phase 3 study, patients with S. aureus bacteremia/endocarditis were randomly assigned to receive a single dose of intravenous exebacase or placebo in addition to standard-of-care antibiotics. The primary efficacy outcome was clinical response at day 14 in the MRSA population.

Results

A total of 259 patients were randomized before the study was stopped for futility based on the recommendation of the unblinded Data Safety Monitoring Board. Clinical response rates at day 14 in the MRSA population (n = 97) were 50.0% (exebacase + antibiotics; 32/64) versus 60.6% (antibiotics alone; 20/33) (P = .392). Overall, rates of adverse events were similar across groups. No adverse events of hypersensitivity related to exebacase were reported.

Conclusions

Exebacase + antibiotics failed to improve clinical response at day 14 in patients with MRSA bacteremia/endocarditis. This result was unexpected based on phase 2 data that established proof-of-concept for exebacase + antibiotics in patients with MRSA bacteremia/endocarditis. In the antibiotics-alone group, the clinical response rate was higher than that seen in phase 2. Heterogeneity within the study population and a relatively small sample size in either the phase 2 or phase 3 studies may have increased the probability of imbalances in the multiple components of day 14 clinical outcome. This study provides lessons for future superiority studies in S. aureus bacteremia/endocarditis. Clinical Trials Registration.NCT04160468

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Staphylococcal InfectionsAnti-Bacterial AgentsBacteremiaMethicillin-Resistant Staphylococcus aureusHumansMaleFemaleMiddle AgedAgedAdultEndocarditis, BacterialTreatment OutcomeStandard of CareDrug Therapy, CombinationStaphylococcus aureus

Stichwörter der Autor:innen

S aureus bacteremiaexebacaselysin

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA.
  • AD Stat Consulting, Guerneville, California, USA.
  • ContraFect Corporation, Yonkers, New York, USA.
  • Stony Point Life Sciences Consulting, Benson, Vermont, USA.
  • Department of Medicine, Mercy Health-St. Vincent Medical Center, Toledo, Ohio, USA.
  • Department of Medicine, Olive View-UCLA Medical Center, Sylmar, California, USA.

ORCID-Profile: Vance G Fowler

Förderung

  • ContraFect Corporation
  • HHS
  • Administration for Strategic Preparedness and Response
  • Biomedical Advanced Research and Development Authority
  • Department of Health and Human Services

Zitieren

APA

Fowler, V. G., Das, A. F., Lipka-Diamond, J., Ambler, J. E., Schuch, R., Pomerantz, R., Cassino, C., Jáuregui-Peredo, L., Moran, G. J., Rupp, M. E., Lachiewicz, A. M., Kuti, J. L., Wise, R. A., Kaye, K. S., Zervos, M. J., & Nichols, W. G. (2024). Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT). Clinical Infectious Diseases, 78(6), 1473-1481. https://doi.org/10.1093/cid/ciae043

Vancouver

Fowler VG, Das AF, Lipka-Diamond J, Ambler JE, Schuch R, Pomerantz R, et al. Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT). Clinical Infectious Diseases. 2024;78(6):1473-1481. doi:10.1093/cid/ciae043

BibTeX
@article{Fowler2024,
  author = {Fowler, Vance G and Das, Anita F and Lipka-Diamond, Joy and Ambler, Jane E and Schuch, Raymond and Pomerantz, Roger and Cassino, Cara and Jáuregui-Peredo, Luis and Moran, Gregory J and Rupp, Mark E and Lachiewicz, Anne M and Kuti, Joseph L and Wise, Robert A and Kaye, Keith S and Zervos, Marcus J and Nichols, W Garrett},
  title = {Exebacase in Addition to Standard-of-Care Antibiotics for Staphylococcus aureus Bloodstream Infections and Right-Sided Infective Endocarditis: A Phase 3, Superiority-Design, Placebo-Controlled, Randomized Clinical Trial (DISRUPT)},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {78},
  number = {6},
  pages = {1473--1481},
  doi = {10.1093/cid/ciae043}
}
Kostenlos starten →